BRYAN-GARNIER-&-CO
European investment bank Bryan, Garnier & Co today presented a study that clearly refutes the widespread structural undervaluation of European software vendors. When the usual EV/sales multiples (enterprise value / expected sales for the next year) are related to the average expected growth over three years (CAGR), European software vendors are even trading at a valuation premium of around nine percent (eight percent in the case of SaaS providers) compared to their US competitors.
For this analysis, software analyst Gregory Ramirez compared the valuations of all 95 European-listed and 97 US-listed software vendors between 2006 and 2020, for which there is historical analyst consensus data from Refinitiv. These companies include 29 European and 67 US SaaS vendors.
A superficial look at the simple sales multiples shows that the US providers' multiple of 9.9 over the last 15 years is significantly higher than the 5.6 of their European competitors. However, if the stock market value is not only assessed on the basis of the simple sales multiple, but average growth1 is taken into account and both are placed in relation to each other, a completely different picture emerges. This puts the significance of the sales expectation for the next year into perspective.
For example: if in April 2021 Salesforce shares were trading at a revenue multiple of 10 (10x expected revenue in 2022) and the expected average revenue growth (CAGR) for 2020-2023 is 20%, the ratio is 10 / 0.2 / 100 and the newly calculated ratio is 0.50. The analyst did this calculation for the 15 years up to April 2021 and came up with a surprising result, which is that the valuations of software companies on the European stock exchanges are not only on par with the companies listed in the US, they are slightly higher. For the Europeans, this results in an average valuation that is nine percent higher than that of their US competitors. The same principle applied to the 29 or 67 (US) listed SaaS providers over a four-year period yields almost the same result: here, the average premium is eight percent.
Ramirez explains: "This picture is much closer to the reality of the stock market valuation. This weighting with the average growth rate normalizes the multiples and thus relativises the significance of the short-term growth expectation for a single year.”
The study also shows that the differences in the individual valuations of software providers listed in Europe are wider than those of their US competitors. This dispersion cannot be explained by a significant number of loss-making companies among European software vendors, nor by the liquidity of their shares. Contrary to another common prejudice, the most highly valued European software stocks are by no means always the most liquid, nor are they necessarily listed on the most liquid markets.
Valuation is not decided by the stock market
Bryan, Garnier & Co explain that the heterogeneity of the valuation of European software providers is a result of very different business models, track records and corporate governance. Above all, the degree of maturity of the European companies is very different, while US companies almost always have a long maturation process with numerous financing rounds behind them before going public.
"This makes it clear that the stock exchange location is not decisive for the valuation of a software company. It's all about the quality of the business model and management, the degree of maturity and the track record to date ," explains Greg Revenu, Managing Partner of Bryan, Garnier & Co. This is an important insight, he says, "because for Europeans an IPO in the USA is usually associated with many difficulties .” Pierre Kiecolt-Wahl, Partner and Head of ECM at Bryan, Garnier & Co adds: "If the stock market success of European software companies is ultimately independent of the chosen stock exchange, there is not the slightest argument against an IPO on a European stock exchange. "
WEBINAR:
Debunking the software valuation gap: European software companies going public in the US
Bryan, Garnier & Co will be hosting a webinar on Thursday 27 May
, 10h CET – 10h45
to discuss the report findings in more detail. Join us >>
About Bryan, Garnier & Co (www.bryangarnier.com )
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.
1 CAGR - in this case a three-year moving average of the expected growth rates of the current year and the next two years
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
